A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026 revenue of $90.2 million -- a 3% year-over-year decline against analyst consensus of roughly $419 million for the full year. If you lost money on PHAR, click here to submit your losses for review . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The miss came from the Company's legacy product. RUCONEST sales fell 10% year-over-year to $72.3 million. Although Joenja revenue rose 40% to $17.9 million -- the growth was not enough to offset the decline in RUCONEST. Diluted EPS came in at $0.002, down from $0.006 in the prior-year quarter.
Alongside the results, Pharming reduced its full-year 2026 revenue outlook to $375 million to $395 million, from a prior range of $405 million to $425 million. The revised midpoint of $385 million was approximately $30 million below the previous midpoint and below analyst expectations.
Shareholders who purchased PHAR and suffered a loss are encouraged to have their claim evaluated at no cost . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the PHAR Investigation
Q: How much did PHAR stock drop? A: Shares fell approximately 22% on July 30, 2026 after the Company reported Q2 2026 revenue of $90.2 million and reduced its full-year 2026 revenue outlook to $375 million to $395 million. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: What is the PHAR securities investigation about? A: A securities investigation is pending concerning Pharming Group (PHAR) regarding potentially materially false or misleading statements. Shares fell approximately 22% after the Company disclosed a Q2 revenue decline and a reduced full-year outlook, causing losses for shareholders.
Q: Who is eligible to participate in the PHAR investigation? A: Investors who purchased PHAR stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do PHAR investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my PHAR shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought PHAR and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.
Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
Attorney Advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260804943847/en/
/A%20close-up%20of%20a%20General%20Motors%20corporate%20sign%20by%20lindaparton%20via%20Adobe%20Stock.jpeg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/Zoetis%20sign%20at%20their%20Canadian%20By%20JHVEPhoto.jpeg)
/Microsoft%20headquarters%20By%20Peter.jpeg)
/A%20SoFi%20logo%20on%20an%20office%20building%20by%20Tada%20Images%20via%20Shutterstock.jpg)